홈 > 시장보고서 > 의약품

시장보고서

상품코드

1279681

세계의 전신홍반루푸스 시장(2023-2030년)

Global Systemic Lupus Erythematosus Market - 2023-2030

발행일: 2023년 05월 | 리서치사:

DataM Intelligence | 페이지 정보: 영문 195 Pages | 배송안내 : 1-2일 (영업일 기준)

■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

시장 개요

세계의 전신홍반루푸스 시장은 2022년 18억 9,320만 달러에 달할 것으로 예상되며, 2030년에는 32억 9,570만 달러에 달할 것으로 예상됩니다. 전신홍반루푸스 시장은 예측 기간(2023-2030년) 중 7.3%의 CAGR을 보일 것으로 예상됩니다.

전신홍반루푸스(SLE)는 만성 자가면역질환으로, 면역체계가 건강한 조직을 잘못 공격하여 피부, 관절, 신장, 심장, 폐, 뇌 등에 해를 끼칠 수 있는 질환으로, 주로 여성에게 많이 발생하며 보통 25세에서 45세 사이에 발병합니다.

전신홍반루푸스는 만성적인 염증과 다양한 증상을 유발해 삶의 질을 떨어뜨릴 수 있습니다. 세계의 전신홍반루푸스 시장은 질환에 대한 지식 증가, 진단율의 향상, 새로운 치료법의 발견으로 인해 향후 몇 년 동안 크게 성장할 것으로 예상됩니다.

시장 역학

정부 구상 증가는 세계 전신홍반루푸스 시장의 성장을 가속할 것으로 예상됩니다.
세계 각국 정부는 SLE 치료법과 치료법에 대한 접근성을 높이고, 연구개발에 대한 재정적 지원을 늘리며, 환자들의 치료 결과를 개선하기 위한 규제를 강화하기 위해 노력하고 있습니다.

예를 들어 미국 질병통제예방센터(CDC)의 2022년 보고서에 따르면 CDC-RFA-DP20-2008은 5년간의 협력 협정을 맺은 자금조달 기회 공고(NOFO)이며, 폐쇄형입니다. 이 협력 협정의 기본 목표는 루푸스에 대한 인식과 능력을 향상시키기 위해 전국적인 노력을 기울이는 국내 조직을 지원하고 협력 관계를 구축하는 것입니다.

이 협약은 루푸스의 징후를 인식하고 발견 시 적절한 대응을 할 수 있는 의료진을 늘리는 것을 목표로 합니다. 또한 이 협정은 루푸스 환자의 자가 관리 툴와 서비스에 대한 참여를 증가시켜 환자의 자가 관리 행동을 긍정적으로 변화시키는 것을 목표로 합니다. 따라서 위의 요인들은 예측 기간 중 세계 전신홍반루푸스 시장의 성장을 가속할 것으로 예상됩니다.

세계 전신홍반루푸스 시장은 치료의 부작용에 따른 제약에 직면할 수 있다

기존의 SLE 치료제 중 상당수는 심각한 부작용을 유발할 수 있으며, 환자들의 사용을 방해할 수 있습니다. 환자들은 상당한 부작용이 있는 치료법을 채택하는 것을 꺼려하며, 이는 시장 제약으로 작용할 수 있습니다.

프레드니손은 염증을 억제하고 관절통, 피부 발진 등의 증상을 완화하는 데 도움이 되는 코르티코스테로이드의 일종이지만, 체중 증가, 고혈압, 골다공증과 같은 심각한 부작용이 있을 수 있습니다.

COVID-19의 영향 분석

코로나19의 유행과 함께 전신홍반루푸스(SLE)가 세계 시장에 큰 영향을 미치고 있습니다. SLE 환자의 의료 접근성 제한은 팬데믹의 심각한 영향 중 하나이며, 많은 SLE 환자들은 면역력이 약해 코로나19에 걸리기 쉽기 때문에 의료 기관을 찾는 사람이 줄어들어 질병을 발견하고 치료하는 데 시간이 걸리게 됩니다.

코로나19의 유행은 SLE 치료제 시장 유입을 방해하고, 이로 인해 SLE 치료제가 부족해져 환자와 의료 시스템에 가격 상승으로 이어져 환자 결과에 악영향을 미칠 수 있습니다.

러시아-우크라이나 분쟁 분석

러시아와 우크라이나의 분쟁은 세계 전신홍반루푸스(SLE) 시장, 특히 SLE 치료제 공급망에 의도하지 않은 결과를 초래할 수 있습니다. 우크라이나는 기타 국가에 의약품을 수출하는 중요한 의약품 제조업체가 되고 있습니다. 전쟁으로 인해 생산 시설과 운송 경로가 파괴되거나 폐쇄되면 SLE 치료제 공급망에 영향을 미칠 수 있습니다.

또한 분쟁으로 인해 지역 내 의료 인프라와 접근성이 저하되어 우크라이나 및 주변 지역의 전신홍반루푸스(SLE) 환자들이 진단과 치료를 위해 오랜 시간 동안 기다려야 하는 상황이 발생할 수 있습니다. 그러나 세계 전신홍반루푸스 시장은 다양하며, 의약품 공급이 특정 지역이나 국가에 크게 의존하지 않는다.

Market Overview

The global systemic lupus erythematosus market reached US$ 1,893.2 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 3,295.7 million by 2030. The systemic lupus erythematosus market is expected to exhibit a CAGR of 7.3% during the forecast period (2023-2030).

Systemic lupus erythematosus (SLE) is a chronic autoimmune condition that can harm the skin, joints, kidneys, heart, lungs, and brain by causing the immune system to wrongly target healthy tissues. SLE is more frequent in women and usually occurs between the ages of 25 and 45.

Chronic inflammation and a variety of symptoms can be caused by the condition, lowering a person's quality of life. The global market for systemic lupus erythematosus is predicted to rise significantly in the next years due to increasing knowledge of the disorder, higher rates of diagnosis, and the discovery of novel therapies.

Market Dynamics

The Rising Number of Government Initiatives is Expected to Drive the Global Systemic Lupus Erythematosus Market Growth.

Governments throughout the world are working to enhance access to SLE treatments and therapies, increase monetary support for R&D, and promote regulations that improve outcomes for patients.

For instance, according to the Centers for Disease Control and Prevention (CDC) 2022 report, the CDC-RFA-DP20-2008 is a closed Notice of Funding Opportunity (NOFO) with a 5-year collaboration agreement. The fundamental goal of this cooperation agreement is to support national organizations in undertaking national initiatives to improve lupus awareness and abilities, as well as to build collaborations.

The goal of this agreement is to increase the number of healthcare practitioners who can recognize lupus signs and take appropriate action if it is detected. Furthermore, the agreement intends to increase lupus patients' participation in self-management tools and services, resulting in a favorable shift in their self-management behaviors. Therefore, the above-mentioned factors, are expected to drive growth of the global systemic lupus erythematosus market over the forecast period.

The Global Systemic Lupus Erythematosus Market May Face Constraints Due to Adverse Effects of Treatment.

Many of the existing SLE therapies have potentially serious side effects, which may prevent patients from using them. Patients may be reluctant to adopt therapies that have considerable adverse effects, which can be a big market restriction.

Prednisone is an example of a corticosteroid that can help reduce inflammation and relieve symptoms like joint pain and skin rashes, but it can also have serious adverse effects including weight gain, high blood pressure, and osteoporosis.

COVID-19 Impact Analysis

In the wake of the COVID-19 epidemic, Systemic Lupus Erythematosus (SLE) has had a substantial influence on the global market. Restricted patient access to medical care has been one of the pandemic's significant effects. Delays in identification and treatment occur as a result of fewer individuals seeking medical attention due to the fact that many SLE patients have compromised immune systems and are more likely to develop severe COVID-19.

This can have a detrimental effect on patient outcomes. The COVID-19 pandemic has also hampered the flow of SLE medications into the market, resulting in shortages and raising prices for patients and healthcare systems.

Russia Ukraine Conflict Analysis

The crisis between Russia and Ukraine may have unintended consequences for the worldwide market for systemic lupus erythematosus (SLE), especially for the SLE drug supply chain. Ukraine is becoming a significant pharmaceutical manufacturer, exporting medicines to other nations. The supply chain for SLE drugs may be affected if production facilities or shipping routes are destroyed or shut down as a result of the war.

In addition, the conflict may result in a decline in the region's healthcare infrastructure and accessibility, which would cause SLE patients in Ukraine and the surrounding territories to wait longer for diagnosis and treatments. The worldwide market for SLE is diversified, nevertheless, and does not rely largely on any one area or nation for the provision of medicines.

Segment Analysis

The global systemic lupus erythematosus market is segmented based on drug class, mode of delivery, distribution channel, and region.

The Hospital Pharmacies Segment is Expected to Dominate the Global Systemic Lupus Erythematosus Market.

The systemic lupus erythematosus (SLE) medication distribution is anticipated to be dominated by hospital pharmacies on a worldwide scale accounting market share of 42.4%. Hospital pharmacies may supply patients with the essential drugs and other therapies and are the main point of care for SLE patients, especially those with severe or complex forms of the condition. Personalised drug dosage and monitoring, as well as access to specialised therapies like intravenous infusions or diagnostic testing, are advantages that hospital pharmacists offer.

Additionally, they already have contacts with healthcare professionals, which makes it simpler to prescribe and monitor drugs as well as to communicate and coordinate treatment. Therefore, owing to the above factors, the hospital pharmacies segment is likely to play major role in accelarating the global systemic lupus erythematosus market growth.

Geographical Analysis

North America Region Holds The Largest Market Share of the Global Systemic Lupus Erythematosus Market.

The global systemic lupus erythematosus market is dominated by North America and holds 1/3rd market share, due to a number of factors, first off, there is more knowledge regarding SLE in this area, which has improved knowledge of the condition and available treatments. Second, compared to other locations, North America has a more established healthcare system, which gives SLE sufferers greater access to medical care and specialised therapies.

In addition, there have been more foundations and independent venture firms funding North American biopharmaceutical producers, which has aided in the creation of novel SLE medications and treatments. For instance, in March 2023, AbbVie revealed the findings of a Phase II research in patients with moderately to highly active systemic lupus erythematosus (SLE) with upadacitinib (RINVOQ, 30 mg) administered alone or in combination treatment (ABBV-599) with a Bruton's Tyrosine Kinase inhibitor (elsubrutinib, 60 mg) once daily.

Competitive Landscape

The major global players in the market include: Anthera Pharmaceuticals, Eli Lilly, GlaxoSmithKline, F. Hoffmann-La Roche, Pfizer Limited, Sanofi, Lycera Corporation, Bristol-Myers Squibb, ImmuPharma Plc, and Merck KGaA.

Why Purchase the Report?

To visualize the global systemic lupus erythematosus- market segmentation based on drug class, mode of delivery, distribution channel, and region, as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of global systemic lupus erythematosus market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as Excel consisting of key products of all the major players.

The global systemic lupus erythematosus market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Drug Class
3.2. Snippet by Mode of Delivery
3.3. Snippet by Distribution Channel
3.4. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. The rising number of government initiatives is expected to drive the global systemic lupus erythematosus market.
- 4.1.2. Restraints
  - 4.1.2.1. The global systemic lupus erythematosus market may face constraints due to adverse effects of treatment.
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Before COVID-19 Scenario
- 6.1.2. Present COVID-19 Scenario
- 6.1.3. Post COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturer's Strategic Initiatives
6.6. Conclusion

7. By Drug Class

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 7.1.2. Market Attractiveness Index, By Drug Class
7.2. Antimalarial Drugs
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Non-Steroidal Anti-Inflammatory Drugs
7.4. Cytotoxic And Immunosuppressive Drugs
7.5. Biologics
7.6. Others

8. By Mode of Delivery

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Delivery
- 8.1.2. Market Attractiveness Index, By Mode of Delivery
8.2. Intravenous
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Subcutaneous
8.4. Oral
8.5. Topical

9. By Distribution Channel

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Retail Pharmacies*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Hospital Pharmacies
9.4. Online Pharmacies

10. By Region

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 10.1.2. Market Attractiveness Index, By Region
10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Delivery
- 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.2.6.1. The U.S.
  - 10.2.6.2. Canada
  - 10.2.6.3. Mexico
10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Delivery
- 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.3.6.1. Germany
  - 10.3.6.2. The U.K.
  - 10.3.6.3. France
  - 10.3.6.4. Italy
  - 10.3.6.5. Spain
  - 10.3.6.6. Rest of Europe
10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Delivery
- 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.4.6.1. Brazil
  - 10.4.6.2. Argentina
  - 10.4.6.3. Rest of South America
10.5. Asia-Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Delivery
- 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.5.6.1. China
  - 10.5.6.2. India
  - 10.5.6.3. Japan
  - 10.5.6.4. Australia
  - 10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Delivery
- 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis

12. Company Profiles

12.1. Anthera Pharmaceuticals Inc. *
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio and Description
- 12.1.3. Financial Overview
- 12.1.4. Key Developments
12.2. Eli Lilly
12.3. GlaxoSmithKline Plc
12.4. F. Hoffmann-La Roche Ltd
12.5. Pfizer Limited
12.6. Sanofi
12.7. Lycera Corporation
12.8. Bristol-Myers Squibb
12.9. ImmuPharma Plc
12.10. Merck KGaA

LIST NOT EXHAUSTIVE

13. Appendix

13.1. About Us and Services
13.2. Contact Us

02-2025-2992
(주말 및 공휴일 제외)

라이선스 / 가격

PDF & Excel (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 4,350

￦ 6,294,000

PDF & Excel (Multiple User License)

PDF 보고서를 동일 사업장에서 7명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 4,850

￦ 7,017,000

PDF & Excel (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 7,850

￦ 11,358,000

※ 부가세 별도